Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Buy Bristol-Myers (BMY) on Janux Collaboration; Use a Tactical Swing Into a Position Trade
Janux deal (01/22/2026) validates solid-tumor push; healthy cash flow and a 4.6% yield cushion downside — but leverage is high.
Bristol-Myers Squibb's recent collaboration with Janux Therapeutics (announced 01/22/2026) meaningfully derisks an effort to expand in solid tumors an...
PENN Entertainment: The Market Has Given Up — A Tactical Long With Size Controls
A beaten-down gaming operator with steady operating cash and heavy non-operating losses — short-term upside if management executes and the balance sheet behaves.
PENN (approx. $14.22) looks oversold after a year-long drop. The business still generates consistent operating cash (Q3 FY2025 operating cash flow $18...
LVS Earnings Preview: 3 Metrics That Will Move the Stock and a Concrete Trade Plan
Focus on Macau volumes, Singapore margins, and cash returns — an actionable swing trade into next week's report.
Las Vegas Sands enters earnings with improving revenue and operating margins driven by Asia assets. Key datapoints: Q3 2025 revenue $3.33B (+~24% YoY)...
TMC: Speculative Long — Ride the Permit Path While Managing Dilution Risk
Small-cap, pre-revenue deep-sea miner; buy a tactical position on positive permitting momentum with strict stops
TMC The Metals Co (TMC) is a pre-revenue deep-seabed minerals explorer that just filed a consolidated commercial recovery application increasing its e...
Devon Energy: Cash Returns and Lower Leverage Leave Room To Run
A pragmatic long trade — buy for yield, cash flow and debt reduction; protect with a tight stop.
Devon Energy (DVN) is generating steady operating cash flow, cutting net debt and returning capital via dividends and financing activity. At ~ $38.77 ...
Endava: Earnings Noise Has Crushed the Share Price, but Margin Fixes Make This a High-Reward Long
Operational leverage and a tidy cost reset can revive profitability — buying around $7, with a tight stop and layered targets.
Endava's stock has collapsed from its mid-cycle highs after a string of disappointing quarters and margin pressure. The business remains a durable dig...
America Movil: Undervalued Relative to Fundamentals but Without an Obvious Buyer - A Tactical Long
Dominant Latin American footprint, steady dividend, and a muted rerating - buy on a defined risk if you want exposure to comms in the region.
America Movil (AMX) is a high-share telecom incumbent across Latin America with ~300 million wireless customers and strong market positions in Mexico ...
Pick Up LRN on Stabilizing Tech Metrics — A Tactical Long with Defined Risk/Reward
Operational fixes and improving cash flow create a short-to-medium term asymmetric trade after the drawdown
Stride (LRN) has been punished for platform failures and a cluster of lawsuits, but underlying profitability, a strong liquidity position and improvin...
Ring Energy (REI) - A Cheap Play If Acquisition Synergies and Lower Third-Party Costs Stick
Small-cap Permian E&P with strong operating cash flow, heavy asset base and a Q3 accounting loss - trade the mismatch between cash generation and market price
Ring Energy is trading near $1.02 and looks attractively priced relative to its balance sheet and recent operating cash flow. The company has been act...
Uber: Profitable Today, Optionality for Much More Tomorrow - A Long Trade Idea
Buy into durable marketplace economics and improving margins; use a staged entry and tight stop to manage execution risk
Uber is generating meaningful operating cash flow, posting profitable quarters and sitting on a strong asset base. The market is pricing the company f...
Short LEU: The Hidden SWU Pricing Risk Built Into Centrus' Balance Sheet
Inventory, leverage and big financing flows make Centrus vulnerable if separative work unit (SWU) pricing or contract timing slips.
Centrus (LEU) looks richly priced for a company with a suddenly larger debt load, volatile quarter-to-quarter LEU results, and inventory exposed to SW...
Pfizer - Position for an Earnings Surprise; Buy the Dip Into Q1
Q1 preview: improving quarter-to-quarter trends and a chunky dividend make a tactical long into results — defined entry, stop and two upside targets.
Pfizer has shown sequential revenue and EPS acceleration across the first three quarters of fiscal 2025 and meaningful operating cash flow. With the s...